UNSPSC 51383308: Robenacoxib

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13F4NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z588009C7C. The term ROBENACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53). Most nations schedule robenacoxib under HS 29224995 and SITC 51465. As of Q4 2014, ROBENACOXIB remains the US FDA Preferred Term for this commodity. Robenacoxib bears US NLM identifiers UMLS ID C2825257 and NCI Concept Code C80565.

SMILES: CCC1=CC(=C(C=C1)NC2=C(C(=CC(=C2F)F)F)F)CC(=O)O.

UNSPSC 51383308 Robenacoxib, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The three most recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, and generic multi-source pharmaceutical distribution — none of which involve robenacoxib, a veterinary anti-inflammatory medication. State and local governments buying under this code tag are instead acquiring emergency opioid-reversal agents, establishing pharmacy benefit program infrastructure, and sourcing generic pharmaceuticals through authorized wholesalers for public health systems.

Activity under this code appears scattered across health agencies and cooperative purchasing vehicles. Seminole County, Florida (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through a competitive IFB process with quarterly deliveries to its community health building, requiring E-Verify compliance and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration, posted an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities, including Oregon, through three authorized wholesalers with pricing weighted 75 percent on competitiveness and requiring cGMP and Drug Supply Chain Security Act certification. Recent activity centers in Florida, Texas, and Minnesota; the code itself shows a mismatch with its nominal pharmaceutical scope and the actual work being bought.